Loading organizations...
Clinical-stage biopharmaceutical company developing long-acting monoclonal antibodies for respiratory & inflammatory conditions, including asthma.
Aiolos Bio is a clinical-stage biopharmaceutical company developing therapies for respiratory and inflammatory conditions, with dual headquarters in San Francisco, California, and London, United Kingdom. The organization focuses on its lead clinical asset, AIO-001, a long-acting monoclonal antibody targeting the TSLP pathway to treat severe asthma. This biologic is designed to enable a dosing schedule of every six months, significantly reducing the standard patient treatment burden. In October 2023, the enterprise launched with a $245 million Series A funding round co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments. Shortly after this initial financing, the pharmaceutical corporation GSK agreed to acquire the business in January 2024 for a $1 billion upfront payment and up to $400 million in regulatory milestones. Aiolos Bio was founded in 2023 by Khurem Farooq and Tony Adamis.
Aiolos Bio has raised $245.0M across 1 funding round.
Aiolos Bio has raised $245.0M in total across 1 funding round.
Aiolos Bio has raised $245.0M in total across 1 funding round.
Aiolos Bio's investors include Wouter Joustra, Atlas Venture, Amir Zamani, Bain Capital Life Sciences, Forbion, Sofinnova Ventures, RA Capital Management.
Aiolos Bio has raised $245.0M across 1 funding round. Most recently, it raised $245.0M Series A in October 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 24, 2023 | $245.0M Series A | Wouter Joustra, Atlas Venture, Amir Zamani, Bain Capital Life Sciences, Forbion, Sofinnova Ventures | RA Capital Management |